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ABSTRACT 
Lynch syndrome (LS) is caused by germline mutations in MSH2, MLH1, MSH6, and 
PMS2 mismatch-repair genes and leads to a high risk of colorectal and endometrial 
cancer. It was recently shown that constitutional 3´ end deletions of EPCAM can cause 
LS in tissues with MSH2 deficiency. We aim to establish the spectrum of mutations in 
MSH2 associated Lynch Syndrome cases and their clinical implications. 
Probands from 159 families suspected of having LS were enrolled in the study. 
Immunohistochemistry (IHC) and microsatellite instability (MSI) analyses were used on 
the probands of all families. Eighteen cases with MSH2 loss were identified: 8 had 
point mutations in MSH2. In 10 Lynch syndrome families without MSH2 mutations, 
MSH2/EPCAM genomic rearrangement screening was performed with the use of 
multiplex ligation-dependent probe amplification (MLPA) and RT-PCR. 
We report that large germline deletions, encompassing one or more exons of the 
MSH2 gene, cosegregate with the LS phenotype in 23% (8/35) of MSI families tested.  
A new combined deletion EPCAM-MSH2 was identified and characterized by 
breakpoint analysis, encompassing from the 3´end region of EPCAM to the 5´ initial 
sequences of the MSH2 (c.859-1860_MSH2:646-254del). EPCAM-MSH2 fusion 
transcript was isolated. The tumors of the carriers show high-level MSI and MSH2 
protein loss.  
The clinical correlation provided evidence that the type of mutation and the extension of 
the deletions involving the MSH2 gene could have different implications in cancer 
predisposition. Thus, the identification of MSH2/EPCAM rearrangements and their 
comprehensive characterization should be included in the routine mutation screening 
protocols for LS.  
 
 
 
 
 American Association for Cancer Research Copyright © 2011 
 on September 29, 2011cancerpreventionresearch.aacrjournals.orgDownloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on July 26, 2011; DOI:10.1158/1940-6207.CAPR-11-0080
 3
INTRODUCTION 
Hereditary non-polyposis colorectal cancer (HNPCC) or Lynch Syndrome is the most 
frequent autosomal dominant colorectal cancer susceptibility syndrome caused by 
mutations inactivating one of the genes of the mismatch-repair system (MMR), most 
frequently MLH1 and MSH2, and less often in MSH6 and PMS2 (1) (2-4). The 
phenotype of tumors from these patients is characterized by widespread microsatellite 
instability (MSI) and loss of protein expression from the affected enzyme detected by 
immunohistochemical staining (IHQ). This syndrome is characterized by a high risk of 
early onset of colorectal cancer and several other extracolonic malignant tumours, 
especially endometrial cancer in women (5). 
 
Mutations in two of these MMR genes, MSH2 and MLH1, account for the majority 
(about 40%) of the patients with HNPCC (6). Although the majority of the genetic 
defects in the human MMR genes responsible for HNPCC are a result of point 
mutations and small insertions and deletions, a substantial proportion result from gross 
genomic rearrangements. The role of genomic rearrangements in the etiology of 
HNPCC has been under-investigated because the screening for large deletions (e.g., 
by multiplex ligation-dependent probe amplification [MLPA] (7) or other techniques) is 
still not universal in diagnostic laboratories. One mechanism which could originate 
large genomic rearrangements is the unequal homologous recombination between 
repeat sequences with a high degree of homology SINE, including Alu repeats (8). In 
particular, there is a high incidence of genomic deletion in the MSH2 gene (4).  This 
item has been reported as being due to the presence of a higher percentage of 
repetitive elements (Alu repeats) in the MSH2 gene. Most of them are present in the 
first half of the gene, including the 5´ upstream sequence of MSH2 (EPCAM/TACSTD1 
and promoter region of MSH2).  
It has recently been shown that constitutional 3´ end deletions of the EPCAM gene 
(OMIM#185535) (non-MMR gene) can cause Lynch syndrome through the epigenetic 
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silencing of MSH2 in EPCAM-expressing tissues, resulting in tissue-specific MSH2 
deficiency (9). Thus, deletions of the last exon of EPCAM constitute a distinct class 
mutation associated with LS. Several investigators have reported families with EPCAM 
deletions (9),(10),(11),(12),(13).  
 
In a recent study, Kempers et al, 2011 (13), established different cancer risks 
associated with EPCAM deletions depending  on whether a deletion affects only the 
EPCAM gene or both the EPCAM and its neighbouring gene MSH2 (EPCAM–MSH2). 
These risks are then compared with those for Lynch syndrome carriers of a mutation in 
MMR genes. This is the first study that describes the cumulative cancer risks and 
cancer profile of EPCAM deletion carriers. They show a profound difference in the 
frequency of cases of endometrial cancer in this group compared with other Lynch 
syndrome families with mismatch-repair gene mutations. 
 
Strikingly, endometrial cancer was observed only in carriers with large EPCAM 
deletions that extended close to the MSH2 gene. The authors described the cumulative 
risk of endometrial cancer at 70 years of age in EPCAM deletion carriers as being 12%. 
This risk is much lower than that for MSH2 mutation carriers (51%) or combined 
MSH2–EPCAM deletion carriers (55%). These data suggest that the risk for 
endometrial cancer in carriers of EPCAM deletions is dependent on the size and 
location of the deletion. The exact criteria of deletions, conferring a low risk of 
endometrial cancer, remain to be defined by further assessments of endometrial 
cancer incidence in carriers of different EPCAM deletions and analyses of the EPCAM–
MSH2 intergenic region for transcription mediating capacity. 
 
These results highlight, on the one hand, the importance of performing strategies for 
defining the exact extent of rearrangements and, on the other hand, that the 
determination of the tumor spectrum and age-specific cancer risk in families carrying 
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different mutations associated with Lynch syndrome will help to generate optimal 
recognition and surveillance strategies.  
 
This study was designed to confirm the prevalence of large genomic rearrangements in 
MSH2 and EPCAM genes in Spanish families. To characterize them, a study was 
proposed at the molecular level to determine their extent, identify their breakpoints and 
characterize the impact of the genomic alteration on the correct splicing of the gene. 
We also evaluated whether different types of MSH2 gene changes (point mutations or 
deletion extensions affecting MSH2 or both EPCAM-MSH2) were associated with 
distinct clinical characteristics within the present study series. 
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PATIENTS AND METHODS 
Patients 
Samples from 159 independent families were referred for MMR mutation analysis 
under the Junta de Castilla y Leon Cancer Genetic Counselling Program (Spain). The 
criteria for entry into the mutational study were defined in accordance with Amsterdam 
or Bethesda guidelines. Informed consent was obtained from each patient.   
DNA was extracted from blood samples from all of our patients using the MagNa Pure 
Systems (Roche). 
 
Immunohistochemical and tumor microsatellite instability testing. 
Immunohistochemical (IHC) staining of tumors for MLH1, MSH2 and MSH6 genes was 
analyzed by a pathologist in the General Yagüe Hospital, Burgos (Spain). 
Microsatellite instability (MSI) analysis was performed on matched normal and tumor 
DNA pairs using the National Cancer Institute/International Collaborative Group on 
HNPCC reference marker panel (including two mononucleotide repeats: Bat25, Bat26; 
and three dinucleotide repeats: D2S123, D5S346, D17S250). DNA was extracted using 
the DNAeasy Tissue kit (Qiagen). Fluorescently labelled PCR products were detected 
using the ABI 3130 Genetic Analyzer and the GeneScan software. We classified 
tumors as MSI-positive only if two or more markers showed instability (14). 
 
Mutation analysis 
Samples from subjects with MSI were analyzed for the detection of point mutation 
using heteroduplex analysis by capillary array electrophoresis (HA-CAE). This method 
was developed in our laboratory (15) and the validation for MMR genes has been 
recently published (16). 
The selection of genes for analysis was based on IHC results. DNA from peripheral 
blood leukocytes was used for the analysis. Fragments showing an HA-CAE-altered 
pattern were sequenced with the BigDye Terminator Sequencing Kit v3.1 (Applied 
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Biosystems, Forster City, CA, USA) with unlabelled forward and reverse primers on an 
ABI 3100 DNA sequencer (4 capillaries; Applied Biosystems). 
 
MSH2 and EPCAM Genomic rearrangement Identification.  
To detect genomic deletions affecting the EPCAM and MSH2 gene loci, the MLPA 
multiplex ligation-dependent probe assay (MRC-Holland, Amsterdam; The 
Netherlands) was used. The test kits used were SALSA MLPA kits P003 and P008 
(MRC Holland, Amsterdam, the Netherlands) following the manufacturer’s instructions. 
The P003 MLH1/MSH2 kit contains oligonucleotide probes targeting all exons of MSH2 
and an additional probe to test exon 1. The P008 MSH6/PMS2 kit contains probes 
targeting EPCAM/TACSTD1 exons 3 and 8: one 27 kb upstream and the other 15 kb 
upstream from the MSH2 gene. PCR products were analyzed on an ABI 3130 capillary 
sequencer using GeneMapper software (Applied Biosystems, Forster City, CA, USA). 
 
Fusion transcript EPCAM-MSH2. RNA isolation and Reverse Transcription PCR 
(RT-PCR). 
The synthesis of complementary DNA (cDNA) was performed with the High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, Forster City, CA, USA) using 
DNase-treated RNA in the presence of random primers. The cDNA amplification was 
performed with specific primers that encompassed the predicted rearrangement 
designed for the coding sequences flanking the putative mutation. Short amplicons 
from RT-PCR were sequenced with the same primers. TASCTD1-Ex7-FW: 5´-
ggttgtggtgatagcagttg-3´ MSH2-Ex4-Rev: 5´-ggttgaggtcctgataaatg-3´. 
 
Breakpoint characterization and Long Range PCR. 
A CGH array strategy was done to confirm the extension of deletions identified by 
MLPA. A specific Human Array CGH 44K was designed by Nimgenetics for coverage 
of chromosome 2: 47419322-47580004 (NCBI 36) with a high resolution (500bp). 
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Based on the information obtained from the CGH array, the interspersed repeats in 
regions around the breakpoints were examined using the Repeat Masker Program 
(www.repeatmasker.org).  
In order to characterize the rearrangements and determine the exact site of their 
breakpoints, we performed Long-range PCR of gDNA using primers designed to span 
the putative breakpoints: EPCAM-In6Fw: 5´-TCCCATTTTTAGACCCCAAA-3´ and 
MSH2-In3Rv: 5´ GTGGCTCATGCCTGTAATCC-3´. The Expand Long Template PCR 
System (Roche Diagnostics GmbH, Mannheim, Germany) was used according to the 
manufacturer’s protocol. PCR products were separated on a 0.8% agarose gel and 
visualized by ethidium bromide staining. PCR products containing the expected 
rearrangement were cut from the gel and purified using GFX PCR DNA and the Gel 
Band Purification Kit (Illustra, GE Healthcare UK limited, Buckinghamshire, United 
Kingdom). Isolated PCR fragments were sequenced by walking on both strands using 
the Big Dye V3.1 Terminator Kit (Applied Biosystems, Forster City, CA, USA) and an 
automated sequencer. 
 
EPCAM-MSH2 deletion detection  
As a diagnostic tool, we designed a multiplex-PCR strategy based on three primer 
sequences (one forward and two reverse) to screen these deletions in patients’ first 
degree relatives. This analysis of genomic DNA produces a unique band sized 705bp 
when primers EPCAM-In6Fw and MSH2-In3Rv are used. This situation happens in a 
wild-type case, and produces an additional band when the third primer, EPCAM-
In6´Rev: 5´-CAATGTGCAAGACACTGATATGAT-3´, is used in deletion carrier samples 
(Figure 3). The experimental conditions are supplied as supplementary material 
(Supplementary Material 1). 
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RESULTS. 
MSH2 point Mutation Analyses.  
A total of 35 MSI families were tested for point mutation in MMR genes by combining 
HA_CAE and sequencing analysis. Eighteen of these families showed a deficiency in 
the expression of MSH2/MSH6 proteins in tumors and the screening began for the 
MSH2 gene. A total of 8 families with a pathogenic germline mutation were detected in 
the MSH2 gene (Figure 1). Clinicopathological features, molecular findings of the index 
patients and sample numbers are listed in Supplementary material 2. 
 
MSH2/EPCAM Genomic rearrangement Analyses.  
The ten families tested negative for point mutations in MSH2 were screened for the 
presence of large genomic rearrangements in EPCAM/MSH2 using MLPA (Figure 1). 
MLPA detected two different rearrangements in MSH2, involving the deletion of exon 7 
and exons 4-8, in three and four unrelated families, respectively, using the SALSA 
MLPA kit P003 MSH2/MLH1 (Table 1). Also, a new deletion encompassing EPCAM-
MSH2 in two members from an additional family was detected using both the SALSA 
MLPA kit P003 and kit P008 (Table 1). No cases involving EPCAM deletion alone 
(without MSH2 5' involvement) were detected.  
 
Two different rearrangements in MSH2, involving the deletion of exon 7 and exons 4-8, 
were previously confirmed through an RT-PCR analysis and sequencing (16). The 
exact breakpoints were determined in the article with the reference number CAPR-11-
0227. Both of them are positioned within Alu elements. (Table 1) 
In order to confirm the extension of multi-exonic MSH2 deletion involving exons 1_3 in 
the two carriers (cases C43 and C132), we used the SALSA MLPA kit P008 
PMS2/MSH6.  A reduction of the peak area at the probe was observed for the MSH2 
exon, which also exhibited an aberrant hybridization signal for one or two EPCAM 
probes (the one located in exon 8), which was confined to the deletion beginning in the 
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3´ region of the EPCAM gene, located upstream of MSH2 (Fig. 2A). RT-PCR on RNA 
from index subject C43, in which exon 7 of EPCAM is fused to exon 4 of MSH2, was 
detected (Fig. 2C). A CGH-Array analysis was used to determine the extension of the 
deletion. The results obtained indicate a deletion extension in chromosome 2: 
47464677-47492513 (NCBI 36).  
 
Primer pairs were designed to obtain a patient-specific junction fragment, which 
produced a length of approximately 550 bp (Fig. 3A). Sequence analysis of the junction 
fragment confirmed a 28.9 Kb deletion (c. 859-1860_MSH2:646-254del) (Fig. 3B). The 
breakpoints are located within two interspersed elements, one AluY and an AluSx in 
inverse orientation (Fig. 3A). Interestingly, the crossover site lies within a 3-bp 
sequence of perfect identity.  This deletion has not been reported in previous studies, 
but many deletions involving exons 1-3 of MSH2 have been described in the Leiden 
Open Variation Database 
(http://chromium.liacs.nl/LOVD2/colon_cancer/home.php?action=switch_db) and their 
breakpoints have still not been investigated. 
We designed a PCR test based on the discrimination of deletion or wild-type alleles in 
order to screen this complex deletion in first degree relatives of the VA-25 family 
(Figure 3C). This procedure is faster, cheaper and easier than MLPA. 
 
Combined EPCAM-MSH2 deletion was detected in a 34-year-old man diagnosed with 
a primary CCR at the same age (C43 case). An additional asymptomatic 43-year-old 
woman carrier was also detected (C132 case). The pedigree of the family is shown in 
Figure 2B. This family fulfilled the Amsterdam I criteria for LS. There were six cancers 
associated to the Lynch Syndrome spectrum in two consecutive generations, two of 
which were diagnosed before the age of 50. Individuals C43 and C132 were carriers of 
the combined EPCAM–MSH2 deletion. Family members are currently undergoing 
analysis for this mutation to predict their risk of developing LS. 
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Clinical correlations.  
The present patients with deletions in MSH2 were divided into groups (with vs. without) 
involving the EPCAM 3´region gene, and they were compared to index individuals from 
our regional registry known to carry MSH2 point mutations (Table 2).  
 
We compared clinical information of individuals in the study in whom a point mutation in 
MSH2 (N =19) was identified with those in whom such a deletion in the same gene was 
identified, depending on the extension (only MSH2 gene N= 15 or EPCAM-MSH2 gene 
N= 1) (Table 2). The average age of CCR diagnosis for those cases with a point 
mutation was ~47 years, compared to ~ 38 and ~34 years for those in the study with 
deletion abnormalities in males. In females, the average age of CCR diagnosis for 
patients with a point mutation was 50 years, as compared to 33 and ~38 years for 
MSH2 or EPCAM-MSH2 deletion positive cases, respectively. The sex distribution 
(male/female) was approximately 6:5 (MSH2 point mutation) and 1:1 for both cases 
MSH2 or EPCAM-MSH2 deletion. The average age of endometrial diagnosis for those 
cases with a point mutation was 43 years, compared to ~ 51 years for those in the 
study with an MSH2 deletion.   
 
When compared to patients with point mutations, MSH2 deletion patients had a two 
and a half times higher chance of developing endometrial cancer. EPCAM-MSH2 
deletion patients did not present any endometrial cancer in women in the family 
described.  
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DISCUSSION 
In this study, we carried out MSH2/EPCAM MLPA analyses of (10) high risk Lynch 
Syndrome cancer patients with loss of MSH2 protein expression in the tumor.  We 
have found copy number alterations in about 23% of high risk families for HNPCC with 
microsatellite instability (8/35) who were previously screened negative for point 
mutations in MLH1, MSH2 and MSH6 genes. MLPA detected two different 
rearrangements in MSH2 in seven unrelated families and a new deletion 
encompassing EPCAM-MSH2 was identified in an additional family. Therefore, all of 
them were found to involve the MSH2 gene. Particularly, two new rearrangements 
encompassing exon 7 and exons 4-8 deletion in MSH2 were detected in three and four 
non-related families respectively, and an additional deletion affecting both EPCAM and 
its neighbouring gene MSH2 (EPCAM–MSH2). However, the two rearrangements 
involving the MSH2 gene occurred in multiple kindred and, in a paper to be published 
in parallel, we will show evidence of a common origin in the two deletion of MSH2 (data 
published on CAPR-11-0227 manuscript). 
 
Our results provide the first evidence that, as in many other studied populations, large 
genomic changes involving the MSH2 gene is an important event in our HNPCC family 
series (almost 50% of pathogenic mutations). The frequency of large rearrangements 
in MSH2, as compared to MLH1, depends on the studied population. Several studies 
have demonstrated that these rearrangements correspond to between 15% and 55% of 
the mutations in MMR genes (17). In a study of the Spanish population, an 
exceptionally low frequency of rearrangements in MLH1/MSH2 genes (<1.5%) was 
reported (18); though a higher frequency of rearrangements was found in a Basque 
Country population (~25%) (19). Our data imply that the high frequency of deletions in 
this study is caused by strong founder effects in our population.  
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On the other hand, deletions in the EPCAM gene have been reported in several 
populations with a different frequency, from 19% (10) to 40% (9) in Hungarian and 
Dutch populations respectively. In the Spanish cohort, one family carrier of this kind of 
mutation has been identified (~10% incidence) (11). All the subjects of EPCAM deletion 
carriers were selected from patients with tumors with MSH2 loss and MSI who lacked 
an MSH2 or MSH6 point mutation. No deletion confined to the EPCAM gene alone was 
identified in our patient series, but we have identified and characterized a new 
combined deletion EPCAM-MSH2 by breakpoint analysis, encompassing from the 
3´end region of EPCAM (TACSTD1) (exons 8 and 9) to the 5´ initial sequences of the 
MSH2 (exons 1-3). From this, one expressed EPCAM-MSH2 fusion transcript was 
identified and it was predicted to be in frame. The tumors of the carriers show 
highlevels of MSI and MSH2 protein loss. 
 
Knowing the frequency of deletion in the population can significantly influence the 
screening algorithms for patients at risk of HNPCC. Considering these results, as well 
as the rapid and easy of perform techniques for the characterization of these mutations 
(such as MLPA, RT-PCR, CGH-Array and sequencing), we proposed that the mutation 
screening algorithm should begin with MLPA and not with conventional 
screening/scanning methods, especially in cases where the protein expression pattern 
of the tumor shows a loss of MSH2 protein or is unknown. Also, our PCR-based assay 
could be useful for rapid cost-effective HNPCC screening of EPCAM-MSH2 deletion 
first-degree relatives.  
 
The possibility that cancer risks may vary, depending on the type of mismatch repair 
gene mutation, may have significant implications for cancer screening 
recommendations. The proportion of pathogenic point mutations versus 
rearrangements in MSH2 versus EPCAM-MSH2 deletions identified in this set of 
samples is of 50% versus 43.8% versus 6.3%. To the best of our knowledge, the 
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clinical features of families carrying the detected rearrangements were not different 
from those of families exhibiting other types of mutations, despite results published by 
other groups like (13), which showed that endometrial cancer was observed only in 
carriers with large EPCAM deletions that extended close to or into the MSH2 gene.  
 
In conclusion, our data show that large genomic rearrangements occur in MSH2 with a 
high frequency and genetic evidence has been provided that a certain proportion of 
these deletions involve the EPCAM gene.  The need to incorporate techniques to 
routinely detect large genomic rearrangements and confirm the extension of the 
deletions involving the MSH2 gene is emphasized, as it could be involved in the 
predisposing to Lynch syndrome.  
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FIGURE LEGENDS 
Figure 1.  Schematic overview of the MSH2 and EPCAM genetic analysis. HA_CAE 
(Heteroduplex Analysis by Capillary Array Electrophoresis) 
 
Figure 2. (A) Representation of MLPA results of index subject from families VA-25. 
Exon 1 from the MSH2 gene is analyzed in duplicate with two synthetic probe mixes. 
This probe was also present in the SALSA P008 kit used for routine EPCAM 
diagnostics. The bar diagram is also shown. A peak reduction of MSH2 exon 1 and 
EPCAM exon 7 probes was recognized. (B) Pedigree of family VA-25 carrier of a 
combined mutation EPCAM-MSH2 with Lynch-associated tumors. The index subject is 
indicated by an arrow (C-43) and family member carrying the deletion is indicated by 
“C” (Carrier) (C132). The sequencing chromatogram of fusion transcript EPCAM-MSH2 
is also shown. RT-PCR on RNA from index subject C-43, in which exon 7 of EPCAM is 
fused to exon 4 of MSH2, was previously performed. 
 
Figure 3. (A) Structural organization of the EPCAM-MSH2 locus. Exons from both 
EPCAM and MSH2 genes are depicted as blue or green boxes, respectively. The 
positions of the long-range PCR primers are indicated by horizontal red arrows. An 
additional reverse primer used in diagnosed PCR is indicated by a horizontal blue 
arrow.  (B) Long range PCR, using primers flanking the deletion, detects a wild type 
(wt) fragment (555bp) in two carrier VA-25 family members (C-43 and C-132). The 
sequence alignment of the region encompassing the breakpoint is shown. Sequence 
identities are indicated by vertical bars. The breakpoint is indicated in grey. Alu 
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sequences involved in the deletion are highlighted in pink (Alu Y in intron 7 of EPCAM 
gene) and blue (Alu Sx in intron 3 of MSH2 gene). (C) Diagnostic PCR tool in which the 
wt band 705bp appears in both control and deletion carrier DNA, while deleted 
fragment 555bp is only amplified in the deletion carrier DNA. The additional bands in 
the PCR are non-specific products. 
 
TABLES LEGENDS 
 
Table1. Characteristics of the EPCAM/MSH2 Deletions. 
 
Table 2. Mean age at diagnosis of colorectal and endometrial cancers in carriers of a 
mutation in MSH2- associated Lynch syndrome cases. 
* Included the carrier mutation probands and their relatives. SD (Standard Deviation) 
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Table1. Characteristics of the EPCAM/MSH2 Deletions. 
Gen 
Exon 
involved 
Family 
code 
Deletions 
Breakpoint 
homology 
(bp) 
Type of repeat 
element 
Detection Method 
Confirmation Method 
Characterization Method 
MSH2 
4-8 
 
VA17 c.646-1019_1386+2420del 
8 AluSq-AluSp 
 
 
MLPA MSH2/MLH1 kit P003 
 
Junction fragment, RNA 
VA20 c.646-1019_1386+2420del 
CGH-Array, Sequencing Junction fragment. VA32 c.646-1019_1386+2420del 
VA134 c.646-1019_1386+2420del 
7 
 
VA4 c.1077-3513_1276+5655del 
6 
 
AluY-AluSg 
MLPA MSH2/MLH1 kit P003 
 
Junction fragment, RNA 
VA169 c.1077-3513_1276+5655del 
CGH-Array, Sequencing Junction fragment 
VA247 c.1077-3513_1276+5655del 
EPCAM- 
MSH2 
Exons 8-9 of 
EpCAM and    
exons 1-3 of 
MSH2 
VA25 c.859-1860_MSH2:646-254del 3 AluY-AluSx 
MLPA MSH2/MLH1 kit P003 
MLPA MSH6/PMS2 kit P008 
Junction fragment, RNA, FUSION TRANSCRIPT 
CGH-Array, Sequencing Junction fragment. 
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Table 2. Mean age at diagnosis of colorectal and endometrial cancers in carriers of a 
mutation in MSH2- associated Lynch syndrome cases. 
 MSH2 EPCAM-MSH2 
POINT MUTATIONS DELETIONS DELETIONS 
Families 8 7 1 
Mutation carriers 19 15 1 
Colorectal cancer*  23 25 4 
Carriers affected 17 (4 females) 13(2 females) 1 
Mean age at diagnostic          
(years, SD) 
Men 46.71 ±6.24  38.29 ±9.01   33.5±0.71   
Female 50.00±23.72     33.00± 6.89   57.5±3.54   
Endometrial cancer 4 6 0 
Female Carriers affected 4 5 - 
Mean age at diagnostic (years) 43.00±1.41  50.75± 7.37  - 
Ratio of colonic to endometrial cancer in women 
patients 
1:1 1:2.5 4:0 
 
* Included the carrier mutation probands and their relatives. SD (Standard Deviation) 
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